查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961051

全球基因組檢測市場：依產品、檢測類型、技術、適應症、最終用戶和地區劃分 - 市場規模、產業動態、機會分析和預測（2026-2035年）

Global Genomic Testing Market: By Offering, Testing Type, Technology, Indication, End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 372 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球基因組檢測市場正經歷快速且顯著的成長，反映出基因分析在醫療保健和研究領域日益成長的重要性。2025年，該市場規模約為 166.2億美元，預計到2035年將顯著成長至 413.4億美元。這一預期成長意味著2026年至2035年的年複合成長率（CAGR）將達到 9.54%。推動這一令人矚目的成長軌跡的關鍵因素有很多，其中以下一代定序（NGS）技術的進步最為重要。

推動市場擴張的另一個關鍵因素是對個人化醫療日益成長的需求。個人化醫療根據個人獨特的基因譜客製化醫療方案。這種方法有望改善治療效果並減少副作用，使基因組檢測成為現代醫療保健的重要組成部分。此外，隨著疾病早期檢測（尤其是在腫瘤學領域）成為關注的焦點，基因組檢測提供了在疾病早期階段識別癌症生物標記和突變所需的工具，實現及時有效的干預。

市場趨勢

基因組檢測市場的特徵是行業領導者和專業公司之間競爭激烈，它們透過策略聯盟、併購等方式爭奪市場領導地位。這種動態格局反映了每家公司為增強技術能力、擴大市場覆蓋範圍和豐富產品組合所做的努力。 Illumina 利用其先進的平台，滿足各種臨床和研究應用的需求，保持了其在高通量短讀測序領域無可爭議的領導地位。

然而，像 Oxford Nanopore 和 PacBio 這樣的創新者則專注於長讀定序技術，開闢了有利的細分市場，為短讀定序方法無法解決的某些複雜基因組分析提供了獨特的優勢。在服務領域，Natera 和 Exact Sciences 等公司之間的競爭異常激烈，尤其是在有利的腫瘤檢測市場。

Natera 在2024年第四季實現了令人矚目的53%的營收成長，這凸顯了市場領導者若能佔據該細分市場的重要佔有率，將獲得多麼巨大的收益。這一令人矚目的成長不僅證實了腫瘤基因組檢測的商業潛力，也激勵著各公司採取積極的銷售策略，並加大對行銷活動的投入。

成長的核心驅動因子

基因組檢測市場的快速擴張主要受慢性疾病的流行所驅動，其中癌症是推動市場成長的重要因素。根據世界衛生組織（WHO）2024年的資料，癌症仍然是全球主要死因之一，每年約有 2,000萬新發病例。這驚人的數字凸顯了癌症對全球帶來的巨大健康負擔，也進一步加劇了對先進診斷工具的迫切需求。展望未來，世界衛生組織預測，到2050年，癌症發生率將激增77%，這將促使人們對有效且精準的醫療干預措施的需求日益成長。為了應對這一日益嚴峻的挑戰，腫瘤學家正日益利用基因組分析作為癌症治療的關鍵組成部分。

新興機會

次世代定序（NGS）已超越桑格定序和微陣列等傳統技術，穩居基因組檢測市場領先地位。與傳統方法不同，NGS 具有驚人的高通量能力，能夠在一次運行中同時對數百萬條 DNA 鏈進行定序。這項技術飛躍徹底改變了基因組分析，提供了前所未有的速度和準確性，以及前所未有的成本效益。對 NGS 的需求在癌症基因治療領域尤其顯著，因為快速且準確的基因資訊對於開發標靶和個人化療法非常重要。

最佳化障礙

基因組檢測的高昂成本對全球眾多患者而言構成重大障礙，可能減緩整體市場成長。儘管基因組技術取得了令人矚目的進步，並在個人化醫療中展現出顯著優勢，但經濟負擔仍然是一項重大挑戰，尤其是在醫療預算有限的中低收入國家。安裝先進的定序設備、購買專用試劑以及聘請高素質專業人員的成本，都推高了基因組檢測的價格。因此，許多可能受益於這些尖端診斷技術的患者無法負擔相關費用，這可能會限制其廣泛應用。

目錄

第1章 研究架構

  • 研究目標
  • 產品概述
  • 市場區隔

第2章 研究方法

  • 定性研究
    • 一手和二手資料來源
  • 量化研究
    • 一手和二手資料來源
  • 依地區劃分的一手調查受訪者組成
  • 研究假設
  • 市場規模估算
  • 資料三角驗證

第3章 執行摘要：全球基因組檢測市場

第4章 全球基因組檢測市場概要

  • 產業價值鏈分析
    • 原料供應商
    • 製造商
    • 經銷商
    • 終端用戶
  • 行業展望
    • 基因體資料分析
    • 基礎設施和組織需求
    • 區域監管狀況
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度、市場動態與趨勢
      • 成長驅動因素
      • 限制因素
      • 挑戰
      • 主要趨勢
    • 影響評估新冠疫情對市場成長趨勢的影響
    • 市場成長與展望
      • 市場收入估計與預測（2020-2035）
      • 價格趨勢分析
    • 競爭格局概覽
      • 市場集中度
      • 公司佔有率分析（基於價值，2025）
      • 競爭格局圖

    第5章 全球基因體檢測市場分析：依提供內容

    • 主要發現
    • 市場規模及預測（2020-2035）
      • 系統與軟體
      • 試劑與耗材
      • 服務

    第6章 全球基因組檢測市場分析：依檢測類型

    • 主要發現
    • 市場規模及預測，2020-2035
      • 定序解決方案
      • 微陣列解決方案

    第7章 全球基因體檢測市場分析：依技術

    • 主要發現
    • 市場規模及預測，2020-2035
      • 蛋白質體學
      • 藥物基因組學
      • 幹細胞療法
      • 克隆

    第8章 全球基因體檢測市場分析：依適應症

    • 主要發現
    • 市場規模及預測，2020-2035
      • 癌症
      • 氣喘
      • 糖尿病
      • 心臟病
      • 其他適應症

    第9章 全球基因體檢測市場分析：依應用領域

    • 主要發現
    • 市場規模及預測（2020-2035）
      • 藥物發現與開發
      • 疾病診斷
      • 農業生產
      • 其他

    第10章 全球基因組檢測市場分析：依最終用戶

    • 主要發現
    • 市場規模及預測（2020-2035）
    • 醫院和診所
    • 研究中心和學術機構機構
    • 製藥和生技公司
    • 其他

第11章 全球基因體檢測市場：交叉分析

  • 主要見解
  • 市場規模及預測（2020-2035）
    • 依產品、應用和最終用戶劃分

第12章 全球基因體檢測市場分析：依地區劃分

  • 主要見解
  • 市場規模及預測（2020-2035）
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美

第13章 北美基因體檢測市場分析

第14章 歐洲基因組檢測市場分析

第15章 亞太地區基因體檢測市場分析

第16章 馬來西亞基因組檢測市場分析

第17章 泰國基因組檢測市場分析

第18章 中東與非洲基因體檢測市場分析

第19章 阿拉伯聯合大公國（UAE）基因組檢測市場分析

第20章 南美洲基因組檢測市場分析

第21章 巴西基因組檢測市場分析

第22章 公司簡介

  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Eurofins Genomics
  • F. Hoffmann-La Roche
  • Illumina, Inc.
  • QIAGEN
  • Singular Genomics Systems, Inc.
  • Thermo Fisher Scientific, Inc.
  • 其他主要參與者
簡介目錄
Product Code: AA0423400

The global genomic testing market is undergoing rapid and substantial growth, reflecting the increasing importance of genetic analysis across healthcare and research sectors. In 2025, the market is valued at approximately USD 16.62 billion, but projections indicate a remarkable rise to USD 41.34 billion by 2035. This anticipated expansion corresponds to a robust compound annual growth rate (CAGR) of 9.54% over the forecast period from 2026 to 2035. Several key factors are driving this impressive growth trajectory, chief among them being technological advancements in next-generation sequencing (NGS).

Another significant contributor to market expansion is the rising demand for personalized medicine, which tailors medical treatment to an individual's unique genetic profile. This approach promises improved treatment outcomes and reduced side effects, making genomic testing an essential component of modern healthcare. Additionally, early disease detection, particularly in oncology, has become a critical focus, with genomic testing providing the tools necessary to identify cancer biomarkers and mutations at the earliest stages, thereby facilitating timely and targeted interventions.

Noteworthy Market Developments

The genomic testing market is characterized by intense competition, with a mix of well-established industry giants and specialized players vying for leadership through strategic alliances, mergers, and acquisitions. This dynamic landscape reflects companies' efforts to strengthen their technological capabilities, expand their market reach, and enhance their product portfolios. Illumina remains the undisputed leader in high-throughput short-read sequencing, leveraging its advanced platforms to serve a broad range of clinical and research applications.

However, other innovators like Oxford Nanopore and PacBio are successfully carving out profitable niches by focusing on long-read sequencing technologies, which offer unique advantages for certain complex genomic analyses that short-read methods cannot address. In the service arena, companies such as Natera and Exact Sciences are locked in fierce competition, particularly targeting the lucrative oncology testing market.

Natera's remarkable 53% revenue growth in the fourth quarter of 2024 exemplifies the substantial rewards available to market leaders who can capture significant volumes in this segment. This impressive growth not only underscores the commercial potential of oncology genomic testing but also motivates companies to adopt aggressive sales strategies and invest heavily in marketing efforts.

Core Growth Drivers

Chronic diseases serve as the primary driving force behind the rapid expansion of the genomic testing market. Among these diseases, cancer stands out as a particularly significant contributor to market growth. According to the World Health Organization's 2024 updates, cancer continues to be one of the leading causes of death worldwide, with roughly 20 million new cases diagnosed every year. This staggering figure highlights the immense global health burden posed by cancer, which in turn fuels the urgent need for advanced diagnostic tools. Looking ahead, the WHO projects a dramatic 77% increase in cancer incidence by the year 2050, underscoring the escalating demand for effective and precise medical interventions. In response to this growing challenge, oncologists are increasingly turning to genomic profiling as a critical component of cancer care.

Emerging Opportunity Trends

Next-Generation Sequencing (NGS) has firmly established itself as the dominant force within the genomic testing market, surpassing older technologies such as Sanger sequencing and microarrays. Unlike these traditional methods, NGS offers remarkably high-throughput capabilities, enabling the simultaneous sequencing of millions of DNA strands in a single run. This technological leap has revolutionized genomic analysis by providing unparalleled speed and accuracy, coupled with a level of cost-efficiency that was previously unattainable. The growing demand for NGS is especially pronounced in the field of cancer gene therapy, where rapid and precise genetic information is crucial for developing targeted treatments and personalized therapies.

Barriers to Optimization

The high costs associated with genomic testing present a significant barrier to accessibility for a broad range of patient populations around the world, potentially slowing the overall growth of the market. Despite the tremendous advancements in genomic technologies and their proven benefits in personalized medicine, the financial burden remains a critical challenge, particularly in low- and middle-income countries where healthcare budgets are limited. The expense of acquiring sophisticated sequencing equipment, purchasing proprietary reagents, and employing highly specialized personnel contributes to the elevated price of genomic tests. As a result, many patients who could benefit from these cutting-edge diagnostics may find them out of reach, limiting the widespread adoption of genomic testing.

Detailed Market Segmentation

By Offerings, the Reagents and Consumables segment holds a commanding position in the genomic testing market, capturing a substantial 46.7% share. This dominance is deeply rooted in the industry's strategic adoption of the "razor-and-blade" business model, which has been structurally engineered by leading companies to ensure sustained revenue streams. Under this model, the initial sale of sequencing equipment-the "razor"-is complemented by the ongoing, mandatory purchase of proprietary reagents and consumables-the "blades"-which are essential for the operation of these devices. Once a sequencing instrument is installed in a laboratory or clinical setting, it creates a continuous demand for these consumables, generating exponential recurring revenue for manufacturers.

By Testing Type, Sequencing Solutions, particularly Next-Generation Sequencing (NGS), dominate the genomic testing market by commanding an overwhelming 66.73% share. This dominance reflects a significant shift in the role of sequencing technologies, which have evolved from being primarily research tools to becoming the undisputed standard of care in clinical diagnostics. The widespread adoption of NGS is a testament to its unparalleled ability to provide comprehensive, high-resolution genetic information that is critical for accurate diagnosis and personalized treatment planning. One of the key drivers behind this massive market share is the explosive commercial growth of liquid biopsy and Minimum Residual Disease (MRD) testing.

By Applications, the Drug Development and Discovery application stands out as the most significant driver of revenue within the global genomic testing market, accounting for over 46% of the total market income. This dominant position underscores the critical role that genomic testing plays in the pharmaceutical industry's research and development efforts. Pharmaceutical companies increasingly rely on genomic data as a fundamental risk-mitigation tool to navigate the complexities and uncertainties inherent in their multi-billion-dollar R&D pipelines. By integrating genomic insights into the drug discovery process, these companies can better identify promising therapeutic targets, optimize clinical trial designs, and predict patient responses more accurately.

By Technology, stem cell therapy technology holds a commanding position in the genomic testing market, capturing a substantial 42.4% share. This dominance stems from the critical role that genomic testing plays in the manufacturing process of Cell and Gene Therapies (CGT), where it is not merely an optional step but a strict regulatory requirement. Regulatory bodies such as the FDA have established comprehensive guidelines that mandate the use of highly sensitive genomic testing techniques to ensure the safety and efficacy of these advanced therapies. Specifically, the FDA's finalized guidance on human gene therapy products requires manufacturers to rigorously screen for potential "off-target" genetic edits and chromosomal rearrangements.

Segment Breakdown

By Offering:

  • System and Software
  • Reagents & Consumables
  • Services
  • DTC Genomic Testing Service
  • Sale of genomic data

By Testing Type:

  • Sequencing Solution
  • DNA Sequencing
  • RNA Sequencing
  • Methylation Sequencing
  • NGS Library Preparation
  • Sequencing Data Analysis
  • Others
  • Microarray Solution
  • Human Genotyping with Arrays
  • Non-Human Genotyping with Arrays
  • Methylation Array Analysis
  • Microarray Data Analysis
  • Others

By Technology:

  • Proteomics
  • Pharmacogenomics
  • Stem Cell Therapy
  • Cloning

By Indication:

  • Cancer
  • Asthma
  • Diabetes
  • Hearth Diseases
  • Other Indication

By Application:

  • Drug Discovery & Development
  • Disease Diagnosis
  • Agricultural Production
  • Others

By End-User:

  • Hospitals & Clinics
  • Research Centers & Academic Institutions
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region:

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • Malaysia
  • Thailand
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America currently holds the largest share of the genomic testing market, commanding approximately 35% of the global market. This dominant position is largely attributed to a favorable reimbursement landscape that encourages widespread adoption of genomic testing across healthcare providers. High levels of healthcare spending in the region further support market growth, enabling greater investment in advanced diagnostic technologies and infrastructure. The United States, in particular, plays a pivotal role in driving this market leadership.
  • Additionally, strong governmental support acts as a critical catalyst for growth. For example, the National Institutes of Health (NIH) has significantly contributed to advancing genomic research through initiatives like the All of Us Research Program, which by February 2025 had released data on 633,000 participants. This large-scale data resource not only accelerates scientific discovery but also helps integrate genomic insights into clinical practice, further reinforcing North America's leading position in the genomic testing market.

Leading Market Participants

  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Eurofins Genomics
  • F. Hoffmann-La Roche
  • Illumina, Inc.
  • QIAGEN
  • Singular Genomics Systems, Inc.
  • Thermo Fisher Scientific, Inc.
  • Other Prominent players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Genomic Testing Market

Chapter 4. Global Genomic Testing Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Raw Material Supplier
    • 4.1.2. Manufacturers
    • 4.1.3. Distributors
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Genomic Data Analysis
    • 4.2.2. Requisite infrastructure and organization for the entering
    • 4.2.3. Regulatory Landscape W.R.T Region
      • 4.2.3.1. North America Regulations/Laws
      • 4.2.3.2. Europe Regulations/Laws
      • 4.2.3.3. Asia Pacific Regulations/Laws
      • 4.2.3.4. South America Regulations/Laws
      • 4.2.3.5. Middle East & Africa Regulations/Laws
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2035
    • 4.7.2. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2025
    • 4.8.3. Competitor Mapping

Chapter 5. Global Genomic Testing Market Analysis, By Offering

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 5.2.1. System and Software
    • 5.2.2. Reagents & Consumables
    • 5.2.3. Services
      • 5.2.3.1. DTC Genomic Testing Service
      • 5.2.3.2. Sale of genomic data

Chapter 6. Global Genomic Testing Market Analysis, By Testing Type

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 6.2.1. Sequencing Solution
      • 6.2.1.1. DNA Sequencing
      • 6.2.1.2. RNA Sequencing
      • 6.2.1.3. Methylation Sequencing
      • 6.2.1.4. NGS Library Preparation
      • 6.2.1.5. Sequencing Data Analysis
      • 6.2.1.6. Others
    • 6.2.2. Microarray Solution
      • 6.2.2.1. Human Genotyping with Arrays
      • 6.2.2.2. Non-Human Genotyping with Arrays
      • 6.2.2.3. Methylation Array Analysis
      • 6.2.2.4. Microarray Data Analysis
      • 6.2.2.5. Others

Chapter 7. Global Genomic Testing Market Analysis, By Technology

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 7.2.1. Proteomics
    • 7.2.2. Pharmacogenomics
    • 7.2.3. Stem Cell Therapy
    • 7.2.4. Cloning

Chapter 8. Global Genomic Testing Market Analysis, By Indication

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 8.2.1. Cancer
    • 8.2.2. Asthma
    • 8.2.3. Diabetes
    • 8.2.4. Hearth Diseases
    • 8.2.5. Other Indication

Chapter 9. Global Genomic Testing Market Analysis, By Application

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 9.2.1. Drug Discovery & Development
    • 9.2.2. Disease Diagnosis
    • 9.2.3. Agricultural Production
    • 9.2.4. Others

Chapter 10. Global Genomic Testing Market Analysis, By End User

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 10.2.1. Hospitals & Clinics
    • 10.2.2. Research Centers & Academic Institutions
    • 10.2.3. Pharmaceutical & Biotechnology Companies
    • 10.2.4. Others

Chapter 11. Global Genomic Testing Market, Cross Analysis

  • 1.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 11.2.1. By Offering, By Application, By End User

Chapter 12. Global Genomic Testing Market Analysis, By Region

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 12.2.1. North America
      • 12.2.1.1. The U.S.
      • 12.2.1.2. Canada
      • 12.2.1.3. Mexico
    • 12.2.2. Europe
      • 12.2.2.1. Western Europe
        • 12.2.2.1.1. The UK
        • 12.2.2.1.2. Germany
        • 12.2.2.1.3. France
        • 12.2.2.1.4. Italy
        • 12.2.2.1.5. Spain
        • 12.2.2.1.6. Rest of Western Europe
      • 12.2.2.2. Eastern Europe
        • 12.2.2.2.1. Poland
        • 12.2.2.2.2. Russia
        • 12.2.2.2.3. Rest of Eastern Europe
    • 12.2.3. Asia Pacific
      • 12.2.3.1. China
      • 12.2.3.2. India
      • 12.2.3.3. Japan
      • 12.2.3.4. South Korea
      • 12.2.3.5. Australia & New Zealand
      • 12.2.3.6. ASEAN
      • 12.2.3.7. Rest of Asia Pacific
    • 12.2.4. Middle East & Africa
      • 12.2.4.1. UAE
      • 12.2.4.2. Saudi Arabia
      • 12.2.4.3. South Africa
      • 12.2.4.4. Rest of MEA
    • 12.2.5. South America
      • 12.2.5.1. Argentina
      • 12.2.5.2. Brazil
      • 12.2.5.3. Rest of South America

Chapter 13. North America Genomic Testing Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 13.2.1. By Offering
    • 13.2.2. By Testing Type
    • 13.2.3. By Technology
    • 13.2.4. By Indication
    • 13.2.5. By Application
    • 13.2.6. By End User
    • 13.2.7. Cross Analysis
    • 13.2.8. By Country

Chapter 14. Europe Genomic Testing Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 14.2.1. By Offering
    • 14.2.2. By Testing Type
    • 14.2.3. By Technology
    • 14.2.4. By Indication
    • 14.2.5. By Application
    • 14.2.6. By End User
    • 14.2.7. Cross Analysis
    • 14.2.8. By Country

Chapter 15. Asia Pacific Genomic Testing Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 15.2.1. By Offering
    • 15.2.2. By Testing Type
    • 15.2.3. By Technology
    • 15.2.4. By Indication
    • 15.2.5. By Application
    • 15.2.6. By End User
    • 15.2.7. Cross Analysis
    • 15.2.8. By Country

Chapter 16. Malaysia Genomic Testing Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 16.2.1. By Offering
    • 16.2.2. By Testing Type
    • 16.2.3. By Technology
    • 16.2.4. By Indication
    • 16.2.5. By Application
    • 16.2.6. By End User
    • 16.2.7. Cross Analysis

Chapter 17. Thailand Genomic Testing Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 17.2.1. By Offering
    • 17.2.2. By Testing Type
    • 17.2.4. By Indication
    • 17.2.5. By Application
    • 17.2.6. By End User
    • 17.2.7. Cross Analysis

Chapter 18. Middle East and Africa Genomic Testing Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 18.2.1. By Offering
    • 18.2.2. By Testing Type
    • 18.2.3. By Technology
    • 18.2.4. By Indication
    • 18.2.5. By Application
    • 18.2.6. By End User
    • 18.2.7. Cross Analysis
    • 18.2.8. By Country

Chapter 19. UAE Genomic Testing Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 19.2.1. By Offering
    • 19.2.2. By Testing Type
    • 19.2.3. By Technology
    • 19.2.4. By Indication
    • 19.2.5. By Application
    • 19.2.6. By End User
    • 19.2.7. Cross Analysis

Chapter 20. South America Genomic Testing Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 20.2.1. By Offering
    • 20.2.2. By Testing Type
    • 20.2.3. By Technology
    • 20.2.4. By Indication
    • 20.2.5. By Application
    • 20.2.6. By End User
    • 20.2.7. Cross Analysis
    • 20.2.8. By Country

Chapter 21. Brazil Genomic Testing Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 21.2.1. By Offering
    • 21.2.2. By Testing Type
    • 21.2.3. By Technology
    • 21.2.4. By Indication
    • 21.2.5. By Application
    • 21.2.6. By End User
    • 21.2.7. Cross Analysis

Chapter 22. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 22.1. Agilent Technologies, Inc.
  • 22.2. BGI Group
  • 22.3. Bio-Rad Laboratories
  • 22.4. Danaher Corporation
  • 22.5. Eurofins Genomics
  • 22.6. F. Hoffmann-La Roche
  • 22.7. Illumina, Inc.
  • 22.8. QIAGEN
  • 22.9. Singular Genomics Systems, Inc.
  • 22.10. Thermo Fisher Scientific, Inc.
  • 22.11. Other Prominent players